DoH Policies screened during the period: 1st April 2021-30th June 2021

In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.

Documents

NICE Technology Appraisal TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (PDF 341KB)
PDF (340 KB)

NICE Technology Appraisal TA681 - Baricitinib for treating moderate to severe atopic dermatitis (PDF 342KB)
PDF (342 KB)

NICE Technology Appraisal TA682 - Erenumab for preventing migraine (PDF 340KB)
PDF (340 KB)

NICE Technology Appraisal TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (PDF 343KB)
PDF (342 KB)

NICE Technology Appraisal TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (PDF 341KB)
PDF (340 KB)

NICE Technology Appraisal TA688 - Selective internal radiation therapies for treating hepatocellular carcinoma (PDF 513KB)
PDF (513 KB)

NICE Technology Appraisal TA685 - Anakinra for treating Still’s disease (PDF 623KB)
PDF (622 KB)

NICE Public Health Guideline NG146 - Workplace health: long-term sickness absence and capability to work (PDF 562KB)
PDF (561 KB)

NICE Technology Appraisal TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (review of TA593) (PDF 512KB)
PDF (513 KB)

Allied Health Professions (AHP) Education Commissioning Plan (PDF 856KB)
PDF (855 KB)

NICE Public Health Guideline PH43 - Hepatitis B and C testing: people at risk of infection (PDF 514KB)
PDF (513 KB)

The Health Protection (Coronavirus, Wearing of Face Coverings) Regulations (Northern Ireland) 2020 and all applied amendments. (PDF 397KB)
PDF (396 KB)

Substance Use Strategy Consultation Document (PDF 711KB)
PDF (711 KB)

NICE Technology Appraisal TA698 - Acalabrutinib for treating chronic lymphocytic leukaemia (PDF 612KB)
PDF (512 KB)

NICE Technology Appraisal TA691- Avelumab for untreated metastatic Merkel cell carcinoma (part review of TA517) (PDF 512KB)
PDF (511 KB)

NICE Technology Appraisal TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (PDF 516KB)
PDF (516 KB)

NICE Technology Appraisal TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (part review of TA657) (PDF 513KB)
PDF (512 KB)

NICE Technology Appraisal TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (PDF 514KB)
PDF (514 KB)

NICE Technology Appraisal TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (review of TA519) (PDF 512KB)
PDF (513 KB)

NICE Technology Appraisal TA696 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (PDF 624KB)
PDF (623 KB)

NICE Technology Appraisal TA697 Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (PDF 607KB)
PDF (606 KB)

NICE Technology Appraisal TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (PDF 514KB)
PDF (513 KB)

NICE Technology Appraisal TA699 - Ofatumumab for treating relapsing multiple sclerosis (PDF 512KB)
PDF (511 KB)

NICE Technology Appraisal TA704 – Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (PDF 623KB)
PDF (623 KB)

NICE Technology Appraisal TA705 – Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (PDF 513KB)
PDF (513 KB)

NICE Clinical Guideline NG151 - Colorectal cancer (updates and replaces CG131 and TA93) (PDF 514KB)
PDF (513 KB)

The Health Security (EU Exit) Regulations 2021 (PDF 490KB)
PDF (489 KB)

Establishment of a regional Care and Justice Campus (PDF 923KB)
PDF (922 KB)

Covid Certification Service (PDF 852KB)
PDF (851 KB)

Help viewing documents